New Treatment Paradigm for Patients with Anaplastic Oligodendroglial Tumors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F14%3A10210717" target="_blank" >RIV/00216208:11140/14:10210717 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/14:10210717

Výsledek na webu

<a href="http://ar.iiarjournals.org/content/34/4/1587.full.pdf+html" target="_blank" >http://ar.iiarjournals.org/content/34/4/1587.full.pdf+html</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

New Treatment Paradigm for Patients with Anaplastic Oligodendroglial Tumors

Popis výsledku v původním jazyce

Oligodendrogliomas are uncommon tumors in neurooncology that represent about 5% of primary brain malignancies. their high sensitivity to radiotherapy and chemotherapy was observed a long time ago. Nonetheless, the evidence-based proof of the hisnificantly longer survival in patients with oligodendrogliomas treated with combined chemotheray and radiotherapy in comparison to radiootherapy-alone did not exist. The long-term follow-up of two landmark phase III clinical trials: RTOG 9402 and EORTC 26951, recently demonstrated favorable effects of combined radiotherapy and chemotherapy (procarbazine, lomustine and vincristine) in patients with anaplastic oligodendrolglionas and anaplastic oligoastrocytomas carrying the chromosomal mutation of co-deletion of1 p/19q. There is also and increasing role of other molecular bionarkers, such as mutations in the metabolic enzyme isocitrate dehydrogenase 1/2, o6-methylguanine DNA methyltransferase gene promotor methylation, or glioma genome cytosine-

Název v anglickém jazyce

New Treatment Paradigm for Patients with Anaplastic Oligodendroglial Tumors

Popis výsledku anglicky

Oligodendrogliomas are uncommon tumors in neurooncology that represent about 5% of primary brain malignancies. their high sensitivity to radiotherapy and chemotherapy was observed a long time ago. Nonetheless, the evidence-based proof of the hisnificantly longer survival in patients with oligodendrogliomas treated with combined chemotheray and radiotherapy in comparison to radiootherapy-alone did not exist. The long-term follow-up of two landmark phase III clinical trials: RTOG 9402 and EORTC 26951, recently demonstrated favorable effects of combined radiotherapy and chemotherapy (procarbazine, lomustine and vincristine) in patients with anaplastic oligodendrolglionas and anaplastic oligoastrocytomas carrying the chromosomal mutation of co-deletion of1 p/19q. There is also and increasing role of other molecular bionarkers, such as mutations in the metabolic enzyme isocitrate dehydrogenase 1/2, o6-methylguanine DNA methyltransferase gene promotor methylation, or glioma genome cytosine-

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/ED2.1.00%2F03.0076" target="_blank" >ED2.1.00/03.0076: Biomedicínské centrum Lékařské fakulty v Plzni</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

8

Strana od-do

1587-1594

Kód UT WoS článku

000334089200014

EID výsledku v databázi Scopus

—